| Literature DB >> 35048417 |
Isabel Haferland1, Chantal M Wallenwein2, Tanja Ickelsheimer1, Sandra Diehl1, Matthias G Wacker3, Susanne Schiffmann2, Claudia Buerger1, Roland Kaufmann1, Anke Koenig1, Andreas Pinter1.
Abstract
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease of the hair follicles leading to painful lesions, associated with increased levels of pro-inflammatory cytokines. Numerous guidelines recommend antibiotics like clindamycin and rifampicin in combination, as first-line systemic therapy in moderate-to-severe forms of inflammation. HS has been proposed to be mainly an auto-inflammatory disease associated with but not initially provoked by bacteria. Therefore, it has to be assumed that the pro-inflammatory milieu previously observed in HS skin is not solely dampened by the bacteriostatic inhibition of DNA-dependent RNA polymerase. To further clarify the mechanism of anti-inflammatory effects of rifampicin, ex vivo explants of lesional HS from 8 HS patients were treated with rifampicin, and its effect on cytokine production, immune cells as well as the expression of Toll-like receptor 2 (TLR2) were investigated. Analysis of cell culture medium of rifampicin-treated HS explants revealed an anti-inflammatory effect of rifampicin that significantly inhibiting interleukin (IL)-1β, IL-6, IL-8, IL-10 and tumour necrosis factor (TNF)-α production. Immunohistochemistry of the rifampicin-treated explants suggested a tendency for it to reduce the expression of TLR2 while not affecting the number of immune cells.Entities:
Keywords: anti-bacterial agents; anti-inflammatory agent; hidradenitis suppurativa; rifampin; therapeutics
Mesh:
Substances:
Year: 2022 PMID: 35048417 DOI: 10.1111/exd.14531
Source DB: PubMed Journal: Exp Dermatol ISSN: 0906-6705 Impact factor: 4.511